PNGAF
Pangea Wellness Inc.·Consumer Defensive
0.33
0.150%(−0.00)
Close PriceLast Updated: — ET
52W L: $0.0152W H: $0.50
PNGAF NEWS
newsfilecorp.com
1d ago
The Precision Peptide Company Inc. Places Order for 20,000 BPC-157 Transdermal Patches
Highlights Order placed for 20,000 units of the Company's lead product candidate, a needle-free BPC-157 transdermal patch, in preparation for commercial release Initial commercial release of the BPC-157 transdermal patch could begin as early as June 2026 through The Precision Peptide Company website Each patch is formulated to deliver 2 mg of BPC-157, consistent with the 95.5% chromatographic purity and 2.02 mg measured dose per patch independently confirmed in the Company's May 19, 2026 news release Vancouver, British Columbia--(Newsfile Corp. - May 26, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that it has placed an order for 20,000 units of its BPC-157 transdermal patch (the "Patch"), the Company's lead product candidate. The order is intended to support the Patch's planned commercial release.
newsfilecorp.com
6d ago
The Precision Peptide Company (BPC) Expands on Exclusive 50/50 Revenue Share Peptide Partnership with MMA.INC (MMA)
Exclusive Agreement Gives Precision Direct Commercial Access to MMA.INC's Global Combat Sports Ecosystem, Backed by Strategic Advisors Conor McGregor and Donald Trump Jr., Cofounder John Kavanagh and Board Director Laura Sanko Highlights Exclusive access to MMA.INC's global combat sports ecosystem1 of 5M+ social media followers, 530,000 user profiles and 800+ verified gyms across 16 countries MMA.INC's roster includes strategic advisors Conor McGregor (who was announced this week to headline UFC 329 against Max Holloway on July 11, 2026 in his first UFC appearance in five years2) and Donald Trump Jr., cofounder John Kavanagh and board director and UFC commentator Laura Sanko 50/50 net revenue share in Year 1, transitioning to 75/25 in favor of Precision thereafter, with no upfront capital investment All Precision products are U.S. manufactured and third party tested, positioning the Company as a compliance first operator New high margin commercialization vertical into a large and engaged athletic community Vancouver, British Columbia--(Newsfile Corp. - May 21, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "Precision"), a publicly traded wellness company building a platform for high quality peptide formulations, today provides additional detail on its previously announced Exclusive Strategic Marketing Agreement (the "Agreement") with Mixed Martial Arts Group Limited ("MMA"), and outlines the strategic significance of the partnership for the Company's commercialization roadmap. A Differentiated Channel Into the Global Combat Sports Community Under the Agreement, Precision has secured exclusive marketing rights across MMA.INC's digitally connected combat sports ecosystem, which the Company believes represents a highly engaged, performance driven and recovery-focused consumer demographic.
newsfilecorp.com
May 19
The Precision Peptide Company (BPC) Lead Product Achieves 95.5% Purity in Independent Lab Testing, Clearing the Industry Benchmark and Advancing Toward Commercial Launch
Highlights The BPC-157 patch is a wearable, needle-free product, designed to remove the injection barrier that has historically limited consumer adoption of peptide products Results support The Precision Peptide Company Inc.'s continued progression of its lead product toward commercial launch Independent lab results confirm 95.5% chromatographic purity and a quantified 2.02 mg dose of BPC-157 per patch¹ Purity result clears the ≥95% threshold recognized across the peptide industry as the analytical benchmark for credible high purity grade peptide products² Testing performed by independent US analytical laboratory Miraxis Labs (San Diego, California), using Ultra High-Performance Liquid Chromatography with Diode Array Detection (UHPLC-DAD), and certified by two PhD scientists Vancouver, British Columbia--(Newsfile Corp. - May 19, 2026) - The Precision Peptide Company Inc. (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today reports initial third-party test results for its needle free BPC-157 transdermal patch (the "Patch"), the Company's lead product candidate. The Results Independent analytical laboratory Miraxis Labs, based in San Diego, California, has tested the patch and confirmed: 95.5% chromatographic purity 2.02 mg of BPC-157 per patch (quantified potency) Both results were measured using Ultra High-Performance Liquid Chromatography with Diode Array Detection (UHPLC-DAD).
newsfilecorp.com
May 14
The Precision Peptide Company's Chief Scientific Officer Justin Kirkland to Be Featured on The Human Upgrade with Dave Asprey
Vancouver, British Columbia--(Newsfile Corp. - May 14, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today announces that Justin Kirkland, Co-Founder and Chief Scientific Officer of the Company's wholly-owned subsidiary Amino Innovations, will be featured as a guest on an upcoming episode of The Human Upgrade with Dave Asprey. The Human Upgrade, hosted by Dave Asprey, is a platform in the biohacking, longevity, and human performance space, with a global audience built over more than a decade of conversations on health optimization, advanced wellness, and emerging science.
feeds.newsfilecorp.com
May 12
The Precision Peptide Company Inc. Announces Exclusive Strategic Marketing Partnership with Mixed Martial Arts Group Limited
Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or
newsfilecorp.com
May 7
The Precision Peptide Company Nears Commercial Launch of Needle-Free BPC-157 Patch as Final Testing Advances
First wearable peptide patch designed to expand BPC-157 beyond injectables and establish a multi-product transdermal peptide platform under Amino Innovations Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - The Precision Peptide Company (CSE: BPC) (OTCQB: PNGAF) (the "Company" or "BPC"), a publicly traded wellness company focused on advanced peptide formulations and delivery systems, today provides an update on the development of its needle-free BPC-157 transdermal patch - a product designed to give consumers a frictionless route into the peptide category for the first time. The BPC-157 patch is currently in active testing, with results anticipated in the near term.
